Literature DB >> 17872838

Should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? YES.

Shelley R Salpeter1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17872838      PMCID: PMC1949245     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  11 in total

1.  Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis.

Authors:  Shelley R Salpeter; Thomas M Ormiston; Edwin E Salpeter
Journal:  Chest       Date:  2004-06       Impact factor: 9.410

2.  Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma.

Authors:  Shelley R Salpeter; Thomas M Ormiston; Edwin E Salpeter
Journal:  Ann Intern Med       Date:  2004-05-18       Impact factor: 25.391

3.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.

Authors:  Harold S Nelson; Scott T Weiss; Eugene R Bleecker; Steven W Yancey; Paul M Dorinsky
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

Review 4.  The beta-agonist controversy.

Authors:  D R Taylor; M R Sears; D W Cockcroft
Journal:  Med Clin North Am       Date:  1996-07       Impact factor: 5.456

Review 5.  Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids.

Authors:  Shelley R Salpeter; Nicholas S Buckley
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 6.  Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review.

Authors:  Shelley R Salpeter
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

7.  Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.

Authors:  W Castle; R Fuller; J Hall; J Palmer
Journal:  BMJ       Date:  1993-04-17

8.  Tolerance to bronchodilating effects of salmeterol in COPD.

Authors:  J F Donohue; S Menjoge; S Kesten
Journal:  Respir Med       Date:  2003-09       Impact factor: 3.415

Review 9.  Contemporary management of chronic obstructive pulmonary disease: scientific review.

Authors:  Don D Sin; Finlay A McAlister; S F Paul Man; Nick R Anthonisen
Journal:  JAMA       Date:  2003-11-05       Impact factor: 56.272

Review 10.  The beta-adrenoceptor.

Authors:  M Johnson
Journal:  Am J Respir Crit Care Med       Date:  1998-11       Impact factor: 21.405

View more
  1 in total

1.  Beta-agonists: all the facts please.

Authors:  Anthony D D'Urzo
Journal:  Can Fam Physician       Date:  2007-11       Impact factor: 3.275

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.